With the development of immunosuppression, PD‐1 and PD‐L1 inhibitors have demonstrated moderate but long‐lasting OS achievements in a subset of patients with SCLC when combined with platinum‐based chemotherapy [22]. This evidence concerns the gene CD274 and small cell lung carcinoma.